178 related articles for article (PubMed ID: 19431005)
1. Understanding women's experiences with medical abortion: In-depth interviews with women in two Indian clinics.
Ganatra B; Kalyanwala S; Elul B; Coyaji K; Tewari S
Glob Public Health; 2010; 5(4):335-47. PubMed ID: 19431005
[TBL] [Abstract][Full Text] [Related]
2. Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women's experiences.
Fielding SL; Edmunds E; Schaff EA
Perspect Sex Reprod Health; 2002; 34(1):34-40. PubMed ID: 11990637
[TBL] [Abstract][Full Text] [Related]
3. Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients.
Vogel KI; LaRoche KJ; El-Haddad J; Chaumont A; Foster AM
Contraception; 2016 Aug; 94(2):137-42. PubMed ID: 27125893
[TBL] [Abstract][Full Text] [Related]
4. Towards safe abortion access: an exploratory study of medical abortion in Cambodia.
Petitet PH; Ith L; Cockroft M; Delvaux T
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):47-55. PubMed ID: 25702068
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Faucher P; Baunot N; Madelenat P
Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
[TBL] [Abstract][Full Text] [Related]
6. The relationship of contextual factors to women's perceptions of medical abortion.
Harvey SM; Beckman LJ; Roberts Branch M
Health Care Women Int; 2002; 23(6-7):654-65. PubMed ID: 12418986
[TBL] [Abstract][Full Text] [Related]
7. Early pregnancy termination with mifepristone and misoprostol in Norway.
Bjørge L; Johnsen SL; Midbøe G; Augestad G; Økland I; Helland H; Stray-Pedersen S; Iversen OE
Acta Obstet Gynecol Scand; 2001 Nov; 80(11):1056-61. PubMed ID: 11703208
[TBL] [Abstract][Full Text] [Related]
8. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
[TBL] [Abstract][Full Text] [Related]
9. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
[TBL] [Abstract][Full Text] [Related]
10. Women's experiences with the use of medical abortion in a legally restricted context: the case of Argentina.
Ramos S; Romero M; Aizenberg L
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):4-15. PubMed ID: 25702064
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study.
Jensen JT; Harvey SM; Beckman LJ
Am J Obstet Gynecol; 2000 Jun; 182(6):1292-9. PubMed ID: 10871441
[TBL] [Abstract][Full Text] [Related]
12. Knowledge and perceptions of medical abortion among potential users.
Harvey SM; Beckman LJ; Castle MA; Coeytaux F
Fam Plann Perspect; 1995; 27(5):203-7. PubMed ID: 9104607
[TBL] [Abstract][Full Text] [Related]
13. Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone.
Akin A; Dabash R; Dilbaz B; Aktün H; Dursun P; Kiran S; Aksan G; Doğan B; Winikoff B
Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):169-75. PubMed ID: 19565414
[TBL] [Abstract][Full Text] [Related]
14. Social sources of women's emotional difficulty after abortion: lessons from women's abortion narratives.
Kimport K; Foster K; Weitz TA
Perspect Sex Reprod Health; 2011 Jun; 43(2):103-9. PubMed ID: 21651709
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of misoprostol among providers and women seeking post-abortion care in Zimbabwe.
Maternowska MC; Mashu A; Moyo P; Withers M; Chipato T
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):16-25. PubMed ID: 25702065
[TBL] [Abstract][Full Text] [Related]
16. Women's experiences in connection with induced abortion - a feminist perspective.
Aléx L; Hammarström A
Scand J Caring Sci; 2004 Jun; 18(2):160-8. PubMed ID: 15147479
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation.
Hamoda H; Ashok PW; Flett GM; Templeton A
BJOG; 2005 Aug; 112(8):1102-8. PubMed ID: 16045525
[TBL] [Abstract][Full Text] [Related]
18. Assessments of the importance of provider characteristics for abortion care: data from women in Rajasthan, India.
Elul B
Health Care Women Int; 2011 Jan; 32(1):72-95. PubMed ID: 21154075
[TBL] [Abstract][Full Text] [Related]
19. A qualitative study of safe abortion and post-abortion family planning service experiences of women attending private facilities in Kenya.
Penfold S; Wendot S; Nafula I; Footman K
Reprod Health; 2018 Apr; 15(1):70. PubMed ID: 29690897
[TBL] [Abstract][Full Text] [Related]
20. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.
Arvidsson C; Hellborg M; Gemzell-Danielsson K
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):87-91. PubMed ID: 16260342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
